Charles E. Cooley

Array ( [id] => 13325953 [patent_doc_number] => 20180214514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => Compositions and Treatments of Metabolic Disorders Using FGF Binding Protein 3 [patent_app_type] => utility [patent_app_number] => 15/784730 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15784730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14548829 [patent_doc_number] => 10342852 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein [patent_app_type] => utility [patent_app_number] => 15/729420 [patent_app_country] => US [patent_app_date] => 2017-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 1869 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15729420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072369 [patent_doc_number] => 20200190171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => Anti-FSTL3 Antibodies And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/337267 [patent_app_country] => US [patent_app_date] => 2017-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807462 [patent_doc_number] => 20220259297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => COMPOSITIONS AND METHOD FOR TREATING KIDNEY DISEASE [patent_app_type] => utility [patent_app_number] => 16/334680 [patent_app_country] => US [patent_app_date] => 2017-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16334680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724363 [patent_doc_number] => 20180133288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED [patent_app_type] => utility [patent_app_number] => 15/720016 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15720016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12706936 [patent_doc_number] => 20180127478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY [patent_app_type] => utility [patent_app_number] => 15/706538 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15706538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13339813 [patent_doc_number] => 20180221446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => Angiogenically Effective Unit Dose Of FGF And Method Of Administering [patent_app_type] => utility [patent_app_number] => 15/699556 [patent_app_country] => US [patent_app_date] => 2017-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15699556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20254853 [patent_doc_number] => 12427186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Method for treating growth hormone deficiency employing hGH fusion protein [patent_app_type] => utility [patent_app_number] => 16/329317 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 3504 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16329317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14960739 [patent_doc_number] => 20190307847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/327760 [patent_app_country] => US [patent_app_date] => 2017-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12206943 [patent_doc_number] => 20180052169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'TSP1 AS A MARKER FOR CANCER' [patent_app_type] => utility [patent_app_number] => 15/681774 [patent_app_country] => US [patent_app_date] => 2017-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 30148 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15681774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15422567 [patent_doc_number] => 10544197 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => FGF-23 epitope peptide for improving resistance to breakage and eggshell strength [patent_app_type] => utility [patent_app_number] => 15/675022 [patent_app_country] => US [patent_app_date] => 2017-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 5014 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15675022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12117313 [patent_doc_number] => 20180000898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'Method of Treating or Ameliorating Type 1 Diabetes Using FGF21' [patent_app_type] => utility [patent_app_number] => 15/671923 [patent_app_country] => US [patent_app_date] => 2017-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 27990 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15671923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12260612 [patent_doc_number] => 20180079806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY' [patent_app_type] => utility [patent_app_number] => 15/668573 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 42675 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051208 [patent_doc_number] => 20170327551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'METHODS OF USING COMPOSITIONS COMPRISING FUSION VARIANTS OF FGF19 POLYPEPTIDES FOR REDUCING GLUCOSE LEVELS IN A SUBJECT' [patent_app_type] => utility [patent_app_number] => 15/666402 [patent_app_country] => US [patent_app_date] => 2017-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 32583 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15666402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12624552 [patent_doc_number] => 20180100014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => BINDING PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/659177 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15659177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16169516 [patent_doc_number] => 10711066 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-14 [patent_title] => Anti-canine platelet derived growth factor receptor alpha antibody [patent_app_type] => utility [patent_app_number] => 16/318944 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5240 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16318944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15256503 [patent_doc_number] => 20190376985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE [patent_app_type] => utility [patent_app_number] => 16/315805 [patent_app_country] => US [patent_app_date] => 2017-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16315805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977586 [patent_doc_number] => 20170281741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'PEPTIDE AND METHOD FOR REDUCING THE PHOSPHATE REQUIREMENT AND EXCRETIION FROM FARM ANIMALS' [patent_app_type] => utility [patent_app_number] => 15/623450 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 11425 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12980830 [patent_doc_number] => 20170342488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => METHODS OF USING FGF19 MODULATORS [patent_app_type] => utility [patent_app_number] => 15/608603 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569932 [patent_doc_number] => 11318186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => Use of FGF21 in methods of increasing exocrine pancreatic secretion [patent_app_type] => utility [patent_app_number] => 16/304080 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8132 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304080 [rel_patent_id] =>[rel_patent_doc_number] =>)